The American College of Rheumatology recommends that to prevent damage and disability, rheumatoid arthritis should be treated early and aggressively. We now know that inflammation results in joint damage and bone loss very early in the disease process (within the first 2 years), making patients more prone to osteoporosis.

Traditionally, therapy for rheumatoid arthritis has started with aspirin and non-steroidal anti-inflammatory drugs (such as ibuprofen and naproxen) which relieve symptoms of pain and swelling. When these no longer provide relief, disease-modifying agents such as penicillamine, hydroxychloroquine, methotrexate, and gold salts - that actually slow joint destruction - have been used. Two new medications, eflunomide and etanercept, are the first disease-modifying drugs to be approved for rheumatoid arthritis in over 10 years. Unfortunately, many patients still attempt to self-treat until the pain becomes too severe or the inflammation becomes disabling. By this time, the damage may be irreversible.

There are numerous reports in the medical literature of alternatives to oral medications. Non-steroidal anti-inflammatory drugs can be absorbed transdermally (through the skin) after being applied as a cream or gel to the affected site. These medications are commercially available in other countries, such as England. Advantages cited include high levels of medication in the tissues where it is needed, and a low incidence of side effects, such as stomach pain and gastrointestinal bleeding.

At Soldotna Professional Pharmacy we work together with patient and physician to solve medication problems. Your questions are welcome!